Secondary prophylaxis of hepatic encephalopathy in cirrhosis: A double blind randomized controlled trial of L-ornithine L-aspartate versus placebo

被引：0
|
作者：
Varakanahalli, S. [1 ]
Sharma, B. [1 ]
Sachdeva, S. [1 ]
Dahale, A. [1 ]
Srivastava, S. [1 ]
机构：
[1] GB Pant Inst Postgrad Med Educ & Res, Gastroenterol, New Delhi, India
来源：
JOURNAL OF HEPATOLOGY | 2018年 / 68卷
关键词：
D O I：
10.1016/S0168-8278(18)30304-0
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
PS-074
引用
收藏
页码：S43 / S43
页数：1
相关论文
共 50 条
  • [21] l-Ornithine l-Aspartate (LOLA) for the Treatment of Hepatic Encephalopathy in Cirrhosis: Novel Insights and Translation to the Clinic
    Roger F. Butterworth
    Drugs, 2019, 79 : 1 - 3
  • [22] TREATMENT OF MINIMAL HEPATIC ENCEPHALOPATHY: A RANDOMIZED CONTROLLED TRIAL COMPARING LACTULOSE, PROBIOTICS & L- ORNITHINE L-ASPARTATE WITH PLACEBO
    Mittal, Vibhu V.
    Sharma, Praveen
    Sharma, Barjesh
    Sarin, Shiv K.
    HEPATOLOGY, 2009, 50 (04) : 471A - 471A
  • [23] Minimal hepatic encephalopathy: Effect of rifaximin, probiotics and L-ornithine L-aspartate
    Sharma, Kapil
    Pant, Sanjay
    Dwivedi, Manisha
    Misra, S. P.
    Misra, Alok
    Narang, Sushil
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2012, 27 : 275 - 276
  • [24] Pharmacokinetic and Pharmacodynamic Properties of l-Ornithine l-Aspartate (LOLA) in Hepatic Encephalopathy
    Kircheis, Gerald
    Lueth, Stefan
    DRUGS, 2019, 79 (Suppl 1) : 23 - 29
  • [25] Pharmacokinetic and Pharmacodynamic Properties of l-Ornithine l-Aspartate (LOLA) in Hepatic Encephalopathy
    Gerald Kircheis
    Stefan Lüth
    Drugs, 2019, 79 : 23 - 29
  • [26] Efficacy of L-Ornithine L-Aspartate for the Treatment of Hepatic Encephalopathy and Hyperammonemia in Cirrhosis: Systematic Review and Meta-Analysis of Randomized Controlled Trials
    Butterworth, Roger F.
    Kircheis, Gerald
    Hilger, Norbert
    McPhail, Mark J. W.
    JOURNAL OF CLINICAL AND EXPERIMENTAL HEPATOLOGY, 2018, 8 (03) : 301 - 313
  • [27] Efficacy of infusion of L-ornithine L-aspartate in cirrhotic patients with portosystemic encephalopathy: A placebo controlled study
    Abid, S
    Mumtaz, K
    Abbas, Z
    Hamid, S
    Jafri, N
    Shah, HA
    Jafri, W
    JOURNAL OF HEPATOLOGY, 2005, 42 : 84 - 84
  • [28] CLINICAL TRIAL TO EVALUATE THE EFFICACY OF PRIMARY PROPHYLAXIS WITH L-ORNITHINE L-ASPARTATE TO PREVENT THE DEVELOPMENT OF OVERT HEPATIC ENCEPHALOPATHY IN PATIENTS WITH CIRRHOSIS AND ACUTE VARICEAL BLEEDING
    Higuera-de la Tijera, F.
    Servin-Caamano, A. I.
    Salas-Gordillo, F.
    Abdo-Francis, J. M.
    Camacho-Aguilera, J.
    Perez-Hernandez, J. L.
    Jimenez-Ponce, F.
    JOURNAL OF HEPATOLOGY, 2016, 64 : S260 - S260
  • [29] L-ornithine L-aspartate for hepatic encephalopathy: a systematic review with meta-analyses of randomised controlled trials
    Goh, E. T.
    Stokes, C. S.
    Vilstrup, H.
    Gluud, L. L.
    Morgan, M. Y.
    JOURNAL OF HEPATOLOGY, 2017, 66 (01) : S131 - S131
  • [30] Recent studies emphasize advantages of the standard therapy with L-ornithine L-aspartate in hepatic encephalopathy
    Schuster, Kirsten
    VISZERALMEDIZIN, 2013, 29 (05):
12345